REVIEW ARTICLE: INSTRUMENTAL ANALYSIS OF SOFOSBUVIR AND DACLATASVIR IN DIFFERENT MATRICES

Main Article Content

ROSHDY E. SARAYA
MAGDA ELHENAWEE
HANAA SALEH
MAHMOUD M. SEBAIY

Abstract

In this literature review, we will introduce most of up-to-date reported methods that have been developed for determination of two important anti-HCV drugs which are Sofosbuvir and Daclatasvir in their pure form, combined form with other drugs, combined form with degradation products, and in biological samples.

Downloads

Download data is not yet available.

Article Details

How to Cite
E. SARAYA, R., ELHENAWEE, M., SALEH, H., & M. SEBAIY, M. (2021). REVIEW ARTICLE: INSTRUMENTAL ANALYSIS OF SOFOSBUVIR AND DACLATASVIR IN DIFFERENT MATRICES. Innovat International Journal Of Medical & Pharmaceutical Sciences, 6(3), 1–8. Retrieved from https://www.innovatpublisher.com/index.php/iijmps/article/view/150
Section
Review Article(s)

References

Naser F Al-Tannak, Ahmed Hemdan, and Maya S Eissa, Development of a robust UPLC method for simultaneous determination of a novel combination of sofosbuvir and daclatasvir in human plasma: Clinical application to therapeutic drug monitoring. International Journal of Analytical Chemistry, 2018. 2018: p. 1-9.2. Marc G Ghany, et al., An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology, 2011. 54(4): p. 1433-1444.

Simmonds, P., Genetic diversity and evolution of hepatitis C virus–15 years on. Journal of General Virology, 2004. 85(11): p. 3173-3188.

Bagaglio, S., C. Uberti-Foppa, and G. Morsica, Resistance mechanisms in hepatitis C virus: implications for direct-acting antiviral use. Drugs, 2017. 77(10): p. 1043-1055.

Brian J Kirby, et al., Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir. Clinical pharmacokinetics, 2015. 54(7): p. 677-690.

Caitlin Mullins, Whitney Gibson, and Olga M Klibanov, Harvoni (ledipasvir and sofosbuvir) for hepatitis C. The Nurse practitioner, 2015. 40(11): p. 22-26.

Elias B Chahine, Allana J Sucher, and Brian A Hemstreet, Sofosbuvir/velpatasvir: the first pangenotypic direct-acting antiviralcombination for hepatitis C. Annals of Pharmacotherapy, 2017. 51(1): p. 44-53.

Khalid AM Attia, et al., Application of different analytical techniques for determination of velpatsvir and sofosbuvir in the pharmaceutical preparation. Journal of Liquid Chromatography & Related Technologies, 2018. 41(9): p. 467-473.

Mamdouh R Rezk, Hany H Monir, and Hoda M Marzouk, Spectrophotometric assessment of the brand new antiviral combination: Sofosbuvir and velpatasvir in their pure forms and pharmaceutical formulation. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2019. 213(1): p. 159-166.

Abdel-Gawad, S.A.-N., Simple chromatographic and spectrophotometric determination of sofosbuvir in pure and tablet forms. European Journal of Chemistry, 2016. 7(3): p. 375-379.

Mohamed El-Kassem M Hassouna and MA Mohamed, UV-Spectrophotometric and stability indicating rp-hplc methods for the determination of the hepatitis c virus inhibitor sofosbuvir in tablet dosage form. Analytical Chemistry Letters, 2018. 8(2): p. 217-229.

Mohamed A El Hamd, et al., Validated ultraviolet-spectrometric method for determination of sofosbuvir in tablets formulation. Journal of Applied Pharmaceutical Science 2017. 7(2): p. 114-119.

Bakht Zaman, et al., Development and validation of spectrophotometric method for assay determination and in vitro dissolution studies of sofosbuvir tablets. Journal of the Chemical Society of Pakistan, 2017. 39(6): p. 962-969.

Amira F El-Yazbi, Comparative Validation of the Determination of Sofosbuvir in Pharmaceuticals by Several Inexpensive Ecofriendly Chromatographic, Electrophoretic, and Spectrophotometric Methods. Journal of AOAC International, 2017. 100(4): p. 1000-1007.

N Jagruthi, et al., Development and validation of UV spectroscopic method for the estimation of sofosbuvir in bulk and pharmaceutical dosage form. Asian Journal of Research in Chemistry, 2018. 11(3): p. 563-568.

MM Baker, et al., Validated spectrophotometric and chromatographic methods for analysis of the recently approved hepatitis C antiviral combination ledipasvir and sofosbuvir. Annales pharmaceutiques francaises, 2018. 76(1): p. 16-31.

Maya S Eissa, Simultaneous determination of the brand new two-drug combination for the treatment of hepatitis C: Sofosbuvir/ledipasvir using smart spectrophotometric methods manipulating ratio spectra. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2017. 183: p. 362-370.

Fotouh R Mansour, A new innovative spectrophotometric method for the simultaneous determination of sofosbuvir and ledipasvir. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2018. 188: p. 626-632.

Nisreen F Abo-Talib, Mohamed R El-Ghobashy, and Marwa H Tammam, Spectrophotometric methods for simultaneous determination of sofosbuvir and ledipasvir (harvoni tablet): Comparative study with two generic products. Journal of AOAC International, 2017. 100(4): p. 976-984.

Hanan I EL-Shorbagy, et al., Earth-friendly spectrophotometric methods for simultaneous determination of ledipasvir and sofosbuvir: Application to average content and uniformity of dosage unit testing. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2018. 205(5): p. 398-409.

Amira S Eldin, et al., The development of a new validated HPLC and spectrophotometric methods for the simultaneous determination of daclatasvir and sofosbuvir: antiviral drugs. Journal of Pharmacy and Pharmacology Research, 2017. 1(1): p. 28-42.

Wafaa S Hassan, et al., Comparative study of six sequential spectrophotometric methods for quantification and separation of ribavirin, sofosbuvir and daclatasvir: An application on Laboratory prepared mixture, pharmaceutical preparations, spiked human urine, spiked human plasma, and dissolution test. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2018. 202(5): p. 159-173.

Nada S Abdelwahab and Nehal F Farid, Innovative spectrophotometric methods for determination of newly discovered combination for hepatitis C treatment. Analytical Chemistry Letters, 2016. 6(6): p. 783-794.24. Sherif Abdel-Naby Abdel-Gawad, Validated simultaneous spectrophotometric quantification of a new antiviral combination. European Journal of Chemistry, 2017. 8(1): p. 8-12.

Saraya, R.E., M. Elhenawee, and H. Saleh, Silver Nanoparticles Synthesis for Sensitive Spectrophotometric Determination of Sofosbuvir, Lamivudine, and Ritonavir in Pure Forms and Pharmaceutical Dosage Forms. Journal of AOAC International, 2020. 103(1): p. 140-147.

P Mohan Vikas, et al., Development and validation of new RP-HPLC method for the determination of sofosbuvir in pure form. World Journal of pharmacy and pharmaceutical Sciences, 2016. 5(5): p. 775-781.

Bakht Zaman, Faisal Siddique, and Waseem Hassan, RP-HPLC method for simultaneous determination of sofosbuvir and ledipasvir in tablet dosage form and its application to in vitro dissolution studies. Chromatographia, 2016. 79(23-24): p. 1605-1613.

Ehab F. Elkady and Ahmed A. Aboelwafa, A rapid and optimized LC-MS/MS method for the simultaneous extraction and determination of sofosbuvir and ledipasvir in human plasma. Journal of AOAC International, 2016. 99(5): p. 1252-1259.

Mohamed El-Kassem M Hassouna, Maha Mohammed Abdelrahman, and Mahmoud Abdelfatah Mohamed, Assay and dissolution methods development and validation for simultaneous determination of sofosbuvir and ledipasvir by RP-HPLC method in tablet dosage forms. Journal of Forensic Science & Criminal Investigations, 2017. 1(3): p. 555-562.

Chenwei Pan, et al., Simultaneous determination of ledipasvir, sofosbuvir and its metabolite in rat plasma by UPLC–MS/MS and its application to a pharmacokinetic study. Journal of Chromatography B, 2016. 1008(2): p. 255-259.

Mamdouh R Rezk, Emad B Basalious, and Iman A Karim, Development of a sensitive UPLC-ESI-MS/MS method for quantification of sofosbuvir and its metabolite, GS-331007, in human plasma: application to a bioequivalence study. Journal of pharmaceutical and biomedical analysis, 2015. 114: p. 97-104.

M Nebsen and Eman S Elzanfaly, Stability-indicating method and LC–MS-MS characterization of forced degradation products of sofosbuvir. Journal of chromatographic science, 2016. 54(9): p. 1631-1640.

Mamdouh R Rezk, Emad B Basalious, and Mohammed E Amin, Novel and sensitive UPLC–MS/MS method for quantification of sofosbuvir in human plasma: application to a bioequivalence study. Biomedical chromatography, 2016. 30(9): p. 1354-1362.

Xiaojun Shi, et al., Evaluation of a rapid method for the simultaneous quantification of ribavirin, sofosbuvir and its metabolite in rat plasma by UPLC–MS/MS. Journal of Chromatography B, 2015. 1002(1): p. 353-357.

Mamdouh R Rezk, et al., Quantification of sofosbuvir and ledipasvir in human plasma by UPLC–MS/MS method: Application to fasting and fed bioequivalence studies. Journal of Chromatography B, 2016. 1028(4): p. 63-70.

Alessandra Ariaudo, et al., A UHPLC–MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma. Journal of pharmaceutical and biomedical analysis, 2016. 125(6): p. 369-375.

Bhimana, S. and G.S. Guntuku, High Performance liquid chromatographic Method for the Determination ofSofosbuvir in pharmaceutical dosage forms. Journal of Comprehensive Pharmacy, 2016. 3.

RM Nemade, MN Dole, and SD Sawant, Development and validation of stability indicating rp-hplc method for the estimation of Sofosbuvir by forced degradation studies. World Journal of Pharmacy and Pharmaceutical Sciences, 2017. 6(4): p. 1503-1512.

T Nagaraju, et al., A New RP-HPLC Method for the Simultaneous Assay of SOFOSBUVIR and LEDIPASVIR in Combined Dosage Form. International Journal of Chemtech Research, 2017. 10(7): p. 761-769.

Ola M Abdallah, Ahmed M Abdel-Megied, and Amira S Gouda, Development a validated highly sensitive LC–MS/MS method for simultaneous quantification of Ledipasvir, sofosbuvir and its major metabolite GS-331007 in human plasma: Application to a humanpharmacokinetic study. Journal of pharmaceutical and biomedical analysis, 2017. 143: p. 305-310.

Sarathb Nalla and JVLN Seshagiri Rao, A stability indicating rp-hplc method for simultaneous estimation of velpatasvir and sofosbuvir in combined tablet dosage forms. World Journal of Pharmacy and Pharmaceutical Sciences, 2017. 6(9): p. 1596-1611.

Mohammad Taher Bahrami, et al., Quantification of sofosbuvir in human serum by liquid chromatography with negative ionization mass spectrometry using the parent peak and its source‐induced fragment: Application to a bioequivalence study. Journal of separation science, 2016. 39(14): p. 2702-2709.

Mukthinuthalapati Mathrusri Annapurna, New Stability Indicating Ultrafast Liquid Chromatographic Method for the Determination of Sofosbuvir in Tablets. Asian Journal of Pharmaceutics (AJP): Free full text articles from Asian J Pharm, 2018. 12(01).

Ola M Abdallah, Ahmed M Abdel‐Megied, and Amira S Gouda, Development and validation of LC‐MS/MS method for simultaneous determination of sofosbuvir and daclatasvir in human Plasma: Application to pharmacokinetic study. Biomedical Chromatography, 2018.

María del Mar Contreras, et al., Potential of RP-UHPLC-DAD-MS for the qualitative and quantitative analysis of sofosbuvir in film coated tablets and profiling degradants. Journal of Pharmaceutical Analysis, 2017. 7(4): p. 208-213.

BM Gandhi, AL Rao, and JV Rao, UPLC-MS/MS method for determination of sofosbuvir in human plasma. Annales pharmaceutiques francaises, 2017. 75(4): p. 257-266.

V. Swetha, et al., Method development and validation of rp-hplc method and stress degradation study of determination of sofosbuvir and velpatasvir in bulk

and pharmaceutical formulation. Indian Journal of Pharmaceutical Science & Research, 2018. 8(1): p. 6-11.

Shaadmin N Shaikh and Manjushri P Dabhade, Development and validation of RP-HPLC method for quantitative analysis of sofosbuvir in pure and pharmaceutical formulation. World journal of pharmacy and pharmaceutical sciences, 2017. 6(8): p. 2249-2250.

Noha N Atia, et al., Simultaneous quantitation of two direct acting hepatitis C antivirals (sofosbuvir and daclatasvir) by an HPLC-UV method designated for their pharmacokinetic study in rabbits. Journal of pharmaceutical and biomedical analysis, 2018.

C Vanitha, Bhaskar Reddy, and SV Satyanarayana, Quality-by-design approach to selective stability indicating RP-HPLC method development and validation for estimation of Sofosbuvir in bulk drug. International Journal of Research in Pharmaceutical Sciences, 2018. 9(2): p. 298-308.

Nehal F Farid and Nada S Abdelwahab, Chromatographic analysis of ledipasvir and sofosbuvir: New treatment for chronic hepatitis C infection with application to human plasma. Journal of Liquid Chromatography & Related Technologies, 2017. 40(7): p. 327-332.

Darshan Bhatt, Padmini Thatavarthi, and B Rajkamal, A quantitative RP-HPLC method development and validation for sofosbuvir in bulk and tablet dosage form. Int. J. of Pharmacy and Analytical Research 7(2).

Dalia W Zidan, et al., Investigation of anti-Hepatitis C virus, sofosbuvir and daclatasvir, in pure form, human plasma and human urine using micellar monolithic HPLC-UV method and application to pharmacokinetic study. Journal of Chromatography B, 2018. 1086(8): p. 73-81.

Shahram Miraghaei, et al., Development and validation of a new HPLC-DAD method for quantification of sofosbuvir in human serum and its comparison with LC–MS/MS technique: Application to a bioequivalence study. Journal of Chromatography B, 2017. 1063: p. 118-122.

Stefania Notari, et al., UPLC–MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients. Journal of Chromatography B, 2018. 1073: p. 183-190.

P Swathi, et al., RP-HPLC method development and validation for estimation of Sofosbuvir in pure and tablet dosage form. Innovat International Journal Of Medical & Pharmaceutical Sciences, 2017. 2(4): p. 7-12.58. S Madhavi and A Prameela Rani, Bioanalytical method development and validation for the determination of Sofosbuvir from human plasma. Int J Pharm Pharm Sci, 2017. 9(3): p. 35-41.

Gandla Kumaraswamy, et al., Novel stabilty indicating RP-HPLC method simultaneous determination of sofosbuvir and velpatasvir in bulk and combined tablet dosage forms. Innovat international journal of medical & pharmaceutical sciences, 2017. 2(7): p. 81-85.

K Nagaraju, G Tanuja, and K Divya, Development And Validation Of Stability Indicating RP-HPLC Method For Estimation Of Ledipasvir And Sofosbuvir. International Journal of Engineering Science Invention, 2018. 3(6): p. 42-48.

SK Mastanamma, et al., Development and validation of stability indicating RP-HPLC method for the simultaneous estimation of Sofosbuvir and Ledipasvir in bulk and their combined dosage form. Future Journal of Pharmaceutical Sciences, 2018. 4(3): p. 1-8.

KV Lalitha, J Raveendra Reddy, and N Devanna, Stability indicating RP-HPLC method development and validation for estimation of Sofosbuvir in pharmaceutical dosage form. The Pharma Innovation, 2018. 7(5, Part J): p. 656.

Jaimin P Patel and CAnkit B haudhary, Stability indicating RP-HPLC method development and validation for simultaneous estimation of sofosbuvir and velpatasvir in tablet. World journal of pharmacy and pharmaceutical sciences, 2018. 7(5): p. 813-828.

J Mamatha and N Devanna, Simultaneous rp-hplc method development and it’s validation for estimation of sofosbuvir and velpatasvir in their combined dosage form. rasyan journal of chemistry. 11(1): p. 392-400.

P Harshalatha, KB Chandrasekhar, and MV Chandrasekhar, A novel stability indicating method development and validation for the simultaneous estimation of Velpatasvir & Sofosbuvir in bulk and its pharmaceutical formulations. International Journal of Research in Pharmaceutical Sciences, 2018. 9(2): p. 566-571.

Muhammad S Tahir, et al., Determination of Sofosbuvir and Velpatasvir in Solid Pharmaceutical Dosage Form by HPLC-PDA and its Application to In Vitro Dissolution Studies. Latin american journal of pharmacy, 2018. 37(6): p. 1067-1073.

Susmita, A.G. and G. Rajitha, Development and validation of stability indicating uplc method for simultaneous estimation of sofosbuvir and velpatasvir in tablet dosage form. IJPSR, 2018. 9(11): p. 4764-4769.

Battula Sreenivasa Rao, Mandapati Varaprasad Reddy, and Bhatraju Sreenivasa Rao, Simultaneous analysis of ledipasvir and sofosbuvir in bulk and tablet dosage form by stability indicating high performance liquid chromatographic method. Global journal for research analysis, 2018. 6(4): p. 505-509.

Chintan H Sathiya and Sandip N Badeliya, Analytical method development and validation for simultaneous estimation of sofosbuvir and ledipasvir in tablet dosage form. World journal of pharmacy and pharmaceutical sciences, 2018. 7(7): p. 897-914.

J Saroja, et al., Concurrent estimation of sofosbuvir and velpatasvir in raw and tablets using stability indicating RP-HPLC method. Rasayan J. Chem., 2018. 3(11): p. 1058 - 1066.

Ehab F Elkady and Ahmed A Aboelwafa, Rapid bioanalytical LC-MS/MS method for the simultaneous determination of sofosbuvir and velpatasvir in human plasma-application to a pharmacokinetic study in Egyptian volunteers. Journal of Chromatography B, 2018. 1102-1103(8): p. 116-124.

Stefania Notari, et al., UPLC–MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients. Journal of Chromatography B, 2018. 1073(1): p. 183-190.

B Jahnavi and S Ganapaty, Development and validation of a stability-indicating method for the simultaneous estimation of sofosbuvir and ledipasvir by RP-HPLC. Indian Journal of Pharmaceutical Sciences, 2018. 80(6): p. 1170-1176.

Pranali Yeram, PD Hamrapurkar, and Padmanabh Mukhedkar, Implementation of quality by design approach to develop and validate stability indicating assay method for simultaneous estimation of sofosbuvir and ledipasvir in bulk drugs and tablet formulation. International journal of pharmaceutical sciences and research, 2019. 10(1): p. 180-188.

Ramesh Prasad, Sachin Bhatt, and Kaushlendra Singh, HPLC method for simultaneous estimation of drug release of ledipasvirand sofosbuvir in ledipasvir and sofosbuvir tablets. International journal of pharmaceutical sciences and research, 2019. 10(2): p. 634-641.

M Prashanthi Evangelin, et al., UPLC method development and validation for simultaneous estimation of sofosbuvir and ledipasvir in tablet dosage form. World journal of pharmaceutical

and medical research. 4(3): p. 225-229.

Minou van Seyen, et al., Quantification of second generation direct-acting antivirals daclatasvir, elbasvir, grazoprevir, ledipasvir, simeprevir, sofosbuvir and velpatasvir in human plasma by UPLC-MS/MS. Journal of Chromatography B, 2019. 1110-1111(1): p. 15-24.

Mamdouh R Rezk, Emad B Basalious, and Kamal A Badr, Novel determination of sofosbuvir and velpatasvir in human plasma by UPLC–MS/MS method: application to a bioequivalence study. Biomedical Chromatography, 2018. 32(11): p. 4347-4354.

B Vanaja, et al., Rp-hplc method development and validation for simultaneous estimation of sofosbuvir and velpatasvir in pure and pharmaceutical dosage form. Innovat international journal of medical & pharmaceutical sciences, 2018. 3(1): p. 45-48.

J sandya rani and n devanna, A New RP-HPLC Method Development and Validation for Simultaneous Estimation of Sofosbuvir and Velpatasvir in Pharmaceutical Dosage Form. International Journal of Engineering Technology Science and Research, 2017. 4(11): p. 145-152.

L Memthoib Devi, i., T Rama Mohan Reddy, and K Abbulu, Simultaneous determination and validation of third generation antiviral drugs by RP-HPLC method. Int. J. of Pharmacy and Analytical Research, 2019. 8(1): p. 1-8.

B Balaswami, et al., A new simple stability-indicating RP-HPLC-PDA method for simultaneous estimation of triplicate mixture of sofosbuvir, velpatasvir and voxilaprevir in tablet dosage form. Research Journal of Pharmacy and Technology, 2018. 11(9): p. 4147-4156.

Mamdouh R Rezk, Hany H Monir, and Hoda M Marzouk, Novel determination of a new antiviral combination; sofosbuvir and velpatasvir by high performance thin layer chromatographic method; application to real human samples. Microchemical Journal, 2019. 146(1): p. 828-834.

Mohammad Nabil Abo-Zeid, et al., Efficient HPTLC-dual wavelength spectrodensitometric method for simultaneous determination of sofosbuvir and daclatasvir: Biological and pharmaceutical analysis. Journal of pharmaceutical and biomedical analysis, 2018. 156: p. 358-365.

Fathy M Salama, et al., Application of TLC Densitometric Method for Simultaneous Estimation of the Newly Co-formulated Antiviral Agents Ledipasvir and Sofosbuvir in Their Tablet Dosage Form. Anal. Chem. Lett., 2017. 7(2): p. 241-247.

Samia M El-Gizawy, et al., New, simple and sensitive HPTLC method for simultaneous determination of anti-hepatitis C Sofosbuvir and ledipasvir in rabbit plasma. Journal of Chromatography B, 2018. 1092(5): p. 432-439.

Saraya, R.E., Elhenawee, M. and Saleh, H.,, Development of a high-performance thin-layer chromatographic method for the simultaneous determination of newly co-formulated antiviral drugs sofosbuvir and velpatasvir in their pure forms and tablet dosage form. JPC-Journal of Planar Chromatography-Modern TLC, 2019. 32(2): p. 141-147.

Mahsa Khalili, et al., Chemometric simultaneous determination of Sofosbuvir and Ledipasvir in pharmaceutical dosage form. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2018. 194(5): p. 141-151.

Fathy M Salama, et al., Multivariate Chemometric Models and Application of Genetic Algorithm for Simultaneous Determination of Ledipasvir and Sofosbuvir in Pure Form and in Pharmaceutical Preparation; A Comparative Study. journal of advanced pharmacy research, 2017. 1(4): p. 185-192.

RM Nemade, MN Dole, and SD Sawant, Development and validation of uv-spectrophotometric method for estimation of sofosbuvir in bulk form by absorbance maxima method. World journal of pharmacy and pharmaceutical sciences, 2017. 6(7): p.92. Nada F Atta, Ahmed Galal, and Yousef M Ahmed, Electrochemical Method for the Determination of Three New Anti-Hepatitis C Drugs: Application in Human Blood Serum. Journal of The Electrochemical Society, 2018. 165(10): p. B442-B451.

Astrid Wendt, et al., Chronic hepatitis C: future treatment. Clinical pharmacology: advances and applications, 2014. 6: p. 1.

Julie A Lemm, et al., Identification of hepatitis C virus NS5A inhibitors. Journal of virology, 2010. 84(1): p. 482-491.

Dike Qiu, et al., The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization. Journal of general virology, 2011. 92(11): p. 2502-2511.

Choongho Lee, et al., The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein. Virology, 2011. 414(1): p. 10-18.

Abdalla Shalaby, et al., Spectrophotometric determination of daclatasvir dihydrochloride by ion-pair reaction with bromophenol blue, bromothymol blue and bromocresol green Chemistry Research Journal, 2017. 2(6).

Vikas Kekan, Sachin Gholve, and Omprakash Bhusnure, Development, validation and stability study of UV spectrophotometric method for determination of daclatasvirin bulk and pharmaceutical dosage forms. International Journal of ChemTech Research, 2017. 10(5): p. 281-287.

Mohammad Nabil Abo-Zeid, et al., Ultrasensitive spectrofluorimetric method for rapid determination of daclatasvir and ledipasvir in human plasma and pharmaceutical formulations. Journal of pharmaceutical and biomedical analysis, 2018. 152(1): p. 155-164.

Mohamed A Abdel-Lateef, et al., Micellar spectrofluorimetric protocol for the innovative determination of HCV antiviral (daclatasvir) with enhanced sensitivity: Application to human plasma and stability study. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2019. 206(5): p. 57-64.

Ola M Abdallah, Ahmed M Abdel‐Megied, and Amira S Gouda, Pharmacokinetic evaluation of daclatasvir and ledipasvir in healthy volunteers using a validated highly sensitive spectrofluorimetric method. Luminescence, 2018. 33(6): p. 1094-1100.

Ramadan Ali and Mohamed M Elsutohy, Specific, highly sensitive and simple spectrofluorimetric method for quantification of daclatasvir in HCV human plasma patients and in tablets dosage form. Open Chemistry, 2019. 17(1): p. 116-126.

Maha A Sultan, et al., Stability-indicating micellar enhanced spectro-fluorometric determination of Daclatasvir in its tablet and spiked human plasma. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2018. 211(8): p. 52-58.

Mamdouh R Rezk, et al., Development and validation of sensitive and rapid UPLC–MS/MS method for quantitative determination of daclatasvir in human plasma: Application to a bioequivalence study. Journal of pharmaceutical and biomedical analysis, 2016. 128(2): p. 61-66.

Sonia T Hassib, et al., Reversed-Phase Liquid Chromatographic Method for Determination of Daclatasvir Dihydrochloride and Study of Its Degradation Behavior. Chromatographia, 2017. 80(7): p. 1101-1107.

G Srinivasu, et al., Development and validation of the chiral HPLC method for daclatasvir in gradient elution mode on amylose-based immobilized chiral stationary phase. Chromatographia, 2016. 79(21-22): p. 1457-1467.

MM Baker, et al., Validated stability-indicating HPLC-DAD method for determination of the recently approved hepatitis C antiviral agent daclatasvir. Annales pharmaceutiques francaises, 2017. 75(3): p. 176-184.

Giulio Nannetti, et al., Development and validation of a simple and robust HPLC method with UV detection for quantification of the hepatitis C virus inhibitor daclatasvir in human plasma. Journal of pharmaceutical and biomedical analysis, 2017. 134(3): p. 275-281.

Bakht Zaman and Waseem Hassan, Development of stability indicating HPLC–UV method for determination of daclatasvir and characterization of forced degradation products. Chromatographia, 2018. 81(5): p. 785-797.

Rasha Aboshabana, et al., Two validated spectrofluorimeteric and high performance liquid chromatography (HPLC) methods with fluorescence detection for the analysis of a new anti‐hepatitis Cdrug, daclatasvir hydrochloride, in raw material or tablet form and in biological fluids. Luminescence, 2018.

V Ashok Chakravarthy and BBV Sailaja, Method development and validation of assay and dissolution methods for the estimation of daclatasvir in tablet dosage forms by reverse phase HPLC. Eur J Pharm Med Res, 2016. 3(7): p. 356-364.

Hao Jiang, et al., Multiplexed LC-MS/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma. Journal of pharmaceutical and biomedical analysis, 2015. 107: p. 409-418.

Santhoshi Priya Dandamudi, et al., Validated RP-HPLC method for estimation of daclatasvir in tablet dosage form. International Journal of Advanced Research and Development, 2018. 3(2): p. 1170-1174.114. Varaprasad Jagadabi, et al., A Stability-Indicating UPLC Method for the Determination of Potential Impurities and Its Mass by a New QDa Mass Detector in Daclatasvir Drug Used to Treat Hepatitis C Infection. Journal of chromatographic science, 2018.

Saraya, R.E., Elhenawee, M. and Saleh, H.,, Development of a highly sensitive high‐performance thin‐layer chromatography method for the screening and simultaneous determination of sofosbuvir, daclatasvir, and ledipasvir in their pure forms and their different pharmaceutical formulations. Journal of separation science,, 2018. 41(18): p. 3553-3560.

Shereen M Azab and Amany M Fekry, Electrochemical design of a new nanosensor based on cobalt nanoparticles, chitosan and MWCNT for the determination of daclatasvir: a hepatitis C antiviral drug. RSC Advances, 2017. 7(2): p. 1118-1126.